Apogenix Awarded €3M Grant to Test Brain Cancer Drug Companion Dx | GenomeWeb

NEW YORK (GenomeWeb) – Biopharmaceutical firm Apogenix announced today that it has received a €3 million ($3.4 million) grant from the German Federal Ministry of Education and Research to support its ongoing development of a companion diagnostic for its experimental glioblastoma immunotherapy APG101.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.